The effect of bedtime dosing of antihypertensive drug with both alfa and beta sympatholytic action in high-risk obstructive sleep apnea hypertensive patients

The effect of bedtime dosing of antihypertensive drug with both alfa and beta sympatholytic action in high-risk obstructive sleep apnea hypertensive patients - The VSSPS (Vasodilation vs Sympatholytic antihypertensives on Sleep blood Pressure in hypertensive patients with Sleep apnea syndrome) study.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010600

Enrollment

Registered

2013-04-26

Start date

2009-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension with obstructive sleep apnea syndrome

Interventions

Carvedilol 10-20mg one time dose, followed by Nifedipine 20-40mg one time dose after the 2weeks washout period. Nifedipine 20-40mg one time dose, followed by Carvedilol 10-20mg one time dose after the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hypertensive subjects with OSAS (AHI>15/hr) 1) who were diagnosed previously by the polysomnography, 2) who were unwilling to receive continuous positive airway pressure (CPAP), and whose sleep BP (measured by ABPM) >120/70 mmHg, were recruited.

Exclusion criteria

Exclusion criteria: Exclusion criteria as follows 1) The patients treated with anti-sympathetic nervous activation agents 2) The patients with bedtime dosing of antihypertensive drug 3) The patients with congestive heart failure (more than NYHA II) 4) The patients with malignancy 5) The patients with renal failure (serum creatinine >2.0 mg/dL) or performing hemodialysis or severe liver dysfunction 6) The patients with contraindication of these drugs 7) The patients with past history of serious side effects 8) The patients who is not given informed consent by themselves 9) The patients decided inappropriate subjects for this study by physicians

Design outcomes

Primary

Measure	Time frame
The difference in the inhibition of BP surge during sleep between two groups.	—

Secondary

Measure	Time frame
Maximum, minimum and average BP during sleep, morning BP, AHI	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026